Anixa Biosciences Inc Revenue Growth Rates (ANIX), Current and Historic Growth - CSIMarket
CSIMarket
 


Anixa Biosciences Inc   (NASDAQ: ANIX)
 

ANIX's Revenue Growth by Quarter and Year

Anixa Biosciences Inc 's Revenue results by quarter and year




ANIX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter October -
3rd Quarter July -5.47
2nd Quarter April 0.00
1st Quarter January 0.00
FY -5.47





ANIX Revenue third quarter 2026 Y/Y Growth Comment
Anixa Biosciences Inc in the third quarter 2026 recorded of $ -5.47 millions.

According to the results reported in the third quarter 2026, Anixa Biosciences Inc achieved the best Revenue growth in Major Pharmaceutical Preparations industry. While Anixa Biosciences Inc ' s Revenue no change of 0% ranks overall at the positon no. in the third quarter 2026.




ANIX Revenue ( Y/Y Growth %) 2026
2025 2024 2023
4th Quarter October - - - -
3rd Quarter July - - - -
2nd Quarter April - - - -
1st Quarter January - - - -
FY   - - - -

Financial Statements
Anixa Biosciences Inc 's third quarter 2026 Revenue $ -5.47 millions ANIX's Income Statement
Anixa Biosciences Inc 's third quarter 2025 Revenue $ 0.00 millions Quarterly ANIX's Income Statement


ANIX Revenue (Quarter on Quarter Growth %)

2026
2025 2024 2023
4th Quarter October - - - -
3rd Quarter July - - - -
2nd Quarter April - - - -
1st Quarter January - - - -
FY (Year on Year)   - - - -




Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Anixa Biosciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ANIX's III. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ANIX's III. Quarter Q/Q Revenue Comment


Anixa Biosciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jul 31 2026)
12 Months Ending
(Apr 30 2026)
12 Months Ending
(Jan 31 2026)
12 Months Ending
(Oct 31 2025)
12 Months Ending
(Jul 31 2025)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
In the Jul 31 2026 period, Anixa Biosciences Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Anixa Biosciences Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Jul 31 2026 period, Anixa Biosciences Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Anixa Biosciences Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 






Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ANIX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue no change for the quarter ending Jul 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jul 31 2026
Lakeland Industries Inc -4.49%$ -4.490 millions
Kewaunee Scientific Corporation-6.50%$ -6.499 millions
Nutriband Inc -29.71%$ -29.711 millions


About Anixa Biosciences Inc Revenue Growth Rates (ANIX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Anixa Biosciences Inc (CIK 715446).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-041963
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Anixa Biosciences Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.